InfuSystem Holdings offers strong growth potential and appears attractively valued after reporting positive Q3 2025 earnings results. INFU's Patient Services segment, especially oncology and wound care, is driving revenue growth, while Device Solutions faced a temporary decline. Margin improvements, new contracts, and the Apollo acquisition are enhancing profitability and expanding INFU's market share and efficiency.
InfuSystem (INFU) is prioritizing profitability and margin expansion under new CEO Carrie Lachance, shifting focus from unprofitable revenue streams. INFU's integration of Apollo Medical's billing system and new ERP is expected to drive significant operational efficiencies and margin gains in FY2026. Capital discipline enables INFU to repurchase shares and reduce debt, while growth opportunities in Wound Care and Oncology remain robust.
The consensus price target hints at a 40% upside potential for InfuSystems Holdings (INFU). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
InfuSystems Holdings, Inc. (INFU) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.08 per share a year ago.
InfuSystem eyes third-quarter 2025 gains as rental contracts and ERP upgrades boost margins across Patient Services and Device Solutions.
If you are looking for stocks that are well positioned to maintain their recent uptrend, InfuSystems Holdings (INFU) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
InfuSystems Holdings, Inc. (INFU) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, INFU's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
INFU's new CEO is driving a disciplined, profit-focused strategy, prioritizing margin expansion and operational efficiency over pure top-line growth. Margin expansion is expected from ERP and billing system upgrades, with EBITDA margins projected to reach a run rate of 23% by the end of FY26. Free cash flow is accelerating as growth shifts to less capital-intensive business lines, supporting buybacks, debt reduction, and strategic acquisitions.
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in InfuSystems Holdings (INFU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does InfuSystems Holdings, Inc. (INFU) have what it takes to be a top stock pick for momentum investors? Let's find out.
InfuSystems Holdings (INFU) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.